Turner William D., an insider at Vera Therapeutics Inc (VERA), purchased 32,500 shares of the company on December 14, 2025. The shares were acquired at a price of $15.53 each, bringing the total transaction value to $505,000. Following this purchase, Turner holds a total of 32,500 shares in the company.
This transaction highlights the confidence insiders may have in their company’s future. Vera Therapeutics, a clinical-stage biotechnology firm headquartered in Brisbane, California, focuses on developing transformative treatments for serious immunological diseases. The company’s lead product candidate, atacicept, targets autoimmune diseases such as IgAN and lupus nephritis.
Vera Therapeutics has a market capitalization of $1.6 billion and reported an EPS (TTM) of -3.98. The company plans to release its next earnings report on August 3, 2026, with an estimated EPS of -1.35 and zero revenue expected.
Insider transactions are reported to the SEC, providing transparency into executive sentiment. However, investors should consider these activities alongside broader market trends and other fundamental factors when evaluating potential investment decisions.